New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses ...

SLXN

<p>新的积极的临床前数据表明，在临床相关剂量下，药物成功分布到肝脏、腹膜和肺部，并且肿瘤负担显著减少</p>

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Silexion Therapeutics 报告了积极的临床前数据，表明在系统给药后，SIL204 能够到达并在主要胰腺癌转移部位发挥作用